Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer

The main issue concerning localized prostate cancers is the lack of a suitable marker which could help patients’ stratification at diagnosis and distinguish those with a benign disease from patients with a more aggressive cancer. Circulating Tumor Cells (CTC) are spread in the blood by invasive tumors and could be the ideal marker in this setting. Therefore, we have compiled data from the literature in order to obtain clues about the clinical impact of CTC in patients with localized prostate cancer. Forty-three publications have been found reporting analyses of CTC in patients with non-metastatic prostate cancer. Of these, we have made a further selection of 11 studies targeting patients with clinical or pathological stages T1 and T2 and reporting the clinical impact of CTC. The results of this search show encouraging data toward the use of CTC in patients with early-stage cancer. However, they also highlight the lack of standardized methods providing a highly sensitive and specific approach for the detection of prostate-derived CTC.

Download Full-text

Prospective Study of the Clinical Impact of Epithelial and Mesenchymal Circulating Tumor Cells in Localized Prostate Cancer

Cancer Management and Research ◽

10.2147/cmar.s253997 ◽

2020 ◽

Vol Volume 12 ◽

pp. 4549-4560

Author(s):

Hailong Liu ◽

Jie Ding ◽

Yanyuan Wu ◽

Di Wu ◽

Jun Qi

Keyword(s):

Prostate Cancer ◽

Prospective Study ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Clinical Impact ◽

Localized Prostate Cancer

Download Full-text

2138 CIRCULATING TUMOR CELLS (CTCS) ARE DETECTABLE IN PATIENTS WITH HIGH-RISK, LOCALIZED PROSTATE CANCER THROUGH USE OF THE CELLSEARCH PLATFORM

The Journal of Urology ◽

10.1016/j.juro.2013.02.2047 ◽

2013 ◽

Vol 189 (4S) ◽

Author(s):

Sumanta Pal ◽

Clayton Lau ◽

Miaoling He ◽

Jennifer Linehan ◽

Timothy Wilson ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Localized Prostate Cancer

Download Full-text

Detecting circulating tumor cells (CTCs) in patients with high-risk, localized prostate cancer using the CellSearch platform.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e15178 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e15178-e15178

Author(s):

Sumanta Kumar Pal ◽

Clayton Lau ◽

Miaoling He ◽

Przemyslaw Twardowski ◽

Timothy G. Wilson ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Gleason Score ◽

Prognostic Value ◽

Localized Prostate Cancer ◽

Cellsearch System ◽

Mesenchymal Transition ◽

E Cadherin

e15178 Background: Enumeration of circulating tumor cells (CTCs) using the CellSearch platform has prognostic value in patients with metastatic castration resistant prostate cancer. However, the prognostic value of CTC enumeration in high-risk, localized prostate cancer (HRLPC) remains undefined. Methods: Patients with HRLPC (defined by ≥1 of the following criteria: ≥ cT3a disease, Gleason score 8-10, or PSA > 20 ng/mL) who have chosen prostatectomy for their definitive management were prospectively identified. Patients were consented to receive 4 sequential 30 mL blood draws, each collected in 3 separate 10 mL EDTA tubes. The first 2 blood draws were conducted 2 weeks prior and immediately prior to surgery, while the second 2 blood draws were conducted 4-6 weeks and 3 months following surgery. Within 4 hrs of blood collection, the white blood cell (WBC) fraction was pooled and Ficoll purified. The WBC fraction was transferred to a CellSave tube, and CTCs were enumerated using the CellSearch system. Expression of CD133 and E-cadherin was characterized using the CellSearch system in patients with detectable CTCs. Results: Within 3 monthsof study initiation in Nov 2011, 19 of a planned 37 patients have been accrued. Median age in the cohort was 65 (range, 51-74), and the number of patients with Gleason score 8-10, ≥ cT3a disease, or PSA > 20 ng/mL was 16, 4, and 2, respectively. The majority of patients (17/19, or 89%) had only one high-risk feature. Mean baseline PSA for the cohort was 11.4 (range, 3.4-37). CTCs were detectable in 67% of patients prior to surgery, 27% of patients at 1 month following surgery and 67% of patients at 3 months following surgery. Amongst those patients with detectable CTCs, the median count was 3 (range, 1-7). Further, in these patients, CD133 and E-cadherin were detected in 44% and 46% of specimens assessed, respectively. Full details of these analyses will be provided at the time of the meeting. Conclusions: Using a modified methodology, CTC enumeration using the CellSearch platform is feasible in patients with HRLPC. Interestingly, markers of epithelial-mesenchymal transition and stem cell lineage are detectable in a proportion of patients with localized disease.

Download Full-text

917 Prevalence and prognostic value of circulating tumor cells in blood of patients with localized prostate cancer prior to radical prostatectomy

European Urology Supplements ◽

10.1016/s1569-9056(12)60914-2 ◽

2012 ◽

Vol 11 (1) ◽

pp. e917-e917a

Author(s):

T. Steuber ◽

T. Schlomm ◽

H. Heinzer ◽

U. Michl ◽

S. Riethdorf ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Prognostic Value ◽

Localized Prostate Cancer

Download Full-text

Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes

Cells ◽

10.3390/cells8070688 ◽

2019 ◽

Vol 8 (7) ◽

pp. 688 ◽

Cited By ~ 8

Author(s):

Mohammed Nimir ◽

Yafeng Ma ◽

Sarah A. Jeffreys ◽

Thomas Opperman ◽

Francis Young ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Digital Pcr ◽

Liquid Biopsies ◽

Tumor Biopsy ◽

Highly Sensitive ◽

Castrate Resistant Prostate Cancer ◽

Castrate Resistant

Detection of androgen receptor (AR) variant 7 (AR-V7) is emerging as a clinically important biomarker in castrate resistant prostate cancer (CRPC). Detection is possible from tumor tissue, which is often inaccessible in the advanced disease setting. With recent progress in detecting AR-V7 in circulating tumor cells (CTCs), circulating tumor RNA (ctRNA) and exosomes from prostate cancer patients, liquid biopsies have emerged as an alternative to tumor biopsy. Therefore, it is important to clarify whether these approaches differ in sensitivity in order to achieve the best possible biomarker characterization for the patient. In this study, blood samples from 44 prostate cancer patients were processed for CTCs and ctRNA with subsequent AR-V7 testing, while exosomal RNA was isolated from 16 samples and tested. Detection of AR and AR-V7 was performed using a highly sensitive droplet digital PCR-based assay. AR and AR-V7 RNA were detectable in CTCs, ctRNA and exosome samples. AR-V7 detection from CTCs showed higher sensitivity and has proven specificity compared to detection from ctRNA and exosomes. Considering that CTCs are almost always present in the advanced prostate cancer setting, CTC samples should be considered the liquid biopsy of choice for the detection of this clinically important biomarker.

Download Full-text